{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:09:21Z","timestamp":1788984561014,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Iterum Therapeutics reported by K. A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil\/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens that cause uUTIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with uUTI were randomized to 5 days of sulopenem or 3 days of ciprofloxacin. The primary endpoint was overall success, defined as both clinical and microbiologic response at day 12. In patients with ciprofloxacin-nonsusceptible baseline pathogens, sulopenem was compared for superiority over ciprofloxacin; in patients with ciprofloxacin-susceptible pathogens, the agents were compared for noninferiority. Using prespecified hierarchical statistical testing, the primary endpoint was tested in the combined population if either superiority or noninferiority was declared in the nonsusceptible or susceptible population, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the nonsusceptible population, sulopenem was superior to ciprofloxacin, 62.6% vs 36.0% (difference, 26.6%; 95% confidence interval [CI], 15.1 to 7.4; P &amp;lt;.001). In the susceptible population, sulopenem was not noninferior to ciprofloxacin, 66.8% vs 78.6% (difference, \u221211.8%; 95% CI, \u221218.0 to 5.6). The difference was driven by a higher rate of asymptomatic bacteriuria (ASB) post-treatment in patients on sulopenem. In the combined analysis, sulopenem was noninferior to ciprofloxacin, 65.6% vs 67.9% (difference, \u22122.3%; 95% CI, \u22127.9 to 3.3). Diarrhea occurred more frequently with sulopenem (12.4% vs 2.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sulopenem was noninferior to ciprofloxacin in the treatment of uUTIs. Sulopenem was superior to ciprofloxacin in patients with uUTIs due to ciprofloxacin-nonsusceptible pathogens. Sulopenem was not noninferior in patients with ciprofloxacin-susceptible pathogens, driven largely by a lower rate of ASB in those who received ciprofloxacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT03354598.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac738","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T16:30:57Z","timestamp":1662395457000},"page":"66-77","source":"Crossref","is-referenced-by-count":50,"title":["Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-5196","authenticated-orcid":false,"given":"Michael W","family":"Dunne","sequence":"first","affiliation":[{"name":"Iterum Therapeutics , Old Saybrook, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I","family":"Aronin","sequence":"additional","affiliation":[{"name":"Iterum Therapeutics , Old Saybrook, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F","family":"Das","sequence":"additional","affiliation":[{"name":"Das Statistical Consulting , Guerneville, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Akinapelli","sequence":"additional","affiliation":[{"name":"Iterum Therapeutics , Old Saybrook, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Zelasky","sequence":"additional","affiliation":[{"name":"Iterum Therapeutics , Old Saybrook, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailaja","family":"Puttagunta","sequence":"additional","affiliation":[{"name":"Iterum Therapeutics , Old Saybrook, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen W","family":"Boucher","sequence":"additional","affiliation":[{"name":"Tufts Medicine and Tufts University School of Medicine , Boston Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"2023081717462569600_ciac738-B1","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023081717462569600_ciac738-B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJMcp030027","article-title":"Acute uncomplicated urinary tract infection in women","volume":"349","author":"Fihn","year":"2003","journal-title":"N Engl J Med"},{"key":"2023081717462569600_ciac738-B3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","article-title":"Emergence of extended-spectrum \u03b2-lactamase urinary tract infections among hospitalized emergency department patients in the United States","volume":"77","author":"Talan","year":"2021","journal-title":"Ann Emerg Med"},{"key":"2023081717462569600_ciac738-B4","doi-asserted-by":"crossref","first-page":"e0220265","DOI":"10.1371\/journal.pone.0220265","article-title":"The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017","volume":"14","author":"Critchley","year":"2019","journal-title":"PLoS One"},{"key":"2023081717462569600_ciac738-B5","doi-asserted-by":"crossref","first-page":"e02359","DOI":"10.1128\/spectrum.02359-21","article-title":"Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to nonsusceptible Enterobacterales","volume":"10","author":"Dunne","year":"2022","journal-title":"Microbiol Spectrum"},{"key":"2023081717462569600_ciac738-B6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijid.2022.03.052","article-title":"Regional differences in antibiotic-resistant Enterobacterales urine isolates in the United States","volume":"119","author":"Aronin","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2023081717462569600_ciac738-B7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12879-022-07167-y","article-title":"A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011\u20132020","volume":"22","author":"Dunne","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2023081717462569600_ciac738-B8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.cmi.2020.03.001","article-title":"The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function","volume":"26","author":"ten Doesschate","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023081717462569600_ciac738-B9","first-page":"1525","article-title":"Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all-cause mortality: population-based cohort study","volume":"364","author":"Gharbi","year":"2019","journal-title":"BMJ"},{"key":"2023081717462569600_ciac738-B10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajem.2017.06.041","article-title":"Risk factors for early return visits to the emergency department in patients with urinary tract infection","volume":"36","author":"Jorgensen","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2023081717462569600_ciac738-B11","first-page":"e01832","article-title":"In vitro activity of sulopenem, an oral penem, against urinary isolates of Escherichia coli","volume":"63","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023081717462569600_ciac738-B12"},{"key":"2023081717462569600_ciac738-B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2307\/2531870","article-title":"The B-value: a tool for monitoring data","volume":"44","author":"Lan","year":"1988","journal-title":"Biometrics"},{"key":"2023081717462569600_ciac738-B14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-3758(01)00077-5","article-title":"Optimally weighted, fixed sequence and gatekeeper multiple testing procedures","volume":"99","author":"Westfall","year":"2001","journal-title":"J Stat Plan Infer"},{"key":"2023081717462569600_ciac738-B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"2023081717462569600_ciac738-B16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1086\/511866","article-title":"Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection","volume":"44","author":"Taur","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023081717462569600_ciac738-B17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023081717462569600_ciac738-B18","first-page":"988","volume-title":"Mandell, Douglas, and Bennet. Principles and practice of infectious diseases","author":"Sobel","year":"2020"},{"key":"2023081717462569600_ciac738-B19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.293.8.949","article-title":"Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. A randomized trial","volume":"293","author":"Hooton","year":"2005","journal-title":"JAMA"},{"key":"2023081717462569600_ciac738-B20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jama.2012.80","article-title":"Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis. A randomized trial","volume":"307","author":"Hooton","year":"2012","journal-title":"JAMA"},{"key":"2023081717462569600_ciac738-B21","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1038\/s41467-020-16627-5","article-title":"Invasion of vaginal epithelial cells by uropathogenic Escherichia coli","volume":"11","author":"Brannon","year":"2020","journal-title":"Nat Commun"},{"key":"2023081717462569600_ciac738-B22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2023081717462569600_ciac738-B23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41467-018-03968-5","article-title":"Culturing of female bladder bacteria reveals an interconnected urogenital microbiota","volume":"9","author":"Thomas-White","year":"2018","journal-title":"Nat Commun"},{"key":"2023081717462569600_ciac738-B24","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1128\/AAC.02824-14","article-title":"A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131","volume":"58","author":"Banerjee","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac738\/46223786\/ciac738.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/1\/66\/51141232\/ciac738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/1\/66\/51141232\/ciac738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:46:59Z","timestamp":1692280019000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/1\/66\/6693482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,7]]},"published-print":{"date-parts":[[2023,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac738","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,9,7]]}}}